RBC Capital maintains ConAgra stock rating on inflation concerns By Investing.com

ConAgra shares have fallen 36.7% over the past year to $15.69, trading near a 52-week low of $15.04; RBC reiterated Sector Perform with a $20 PT but flagged rising cost pressures for fiscal 2027 and InvestingPro shows a Fair Value of $19.12. Wells Fargo downgraded the stock to Underweight with a $15 PT citing 2027 EPS risk while UBS remains Neutral with a $20 PT and expects organic sales to beat estimates. The company announced a ~$220M investment to expand chicken production capacity in Fayetteville (creating 100+ jobs) and will report fiscal Q3 2026 earnings on April 1; dividend yield is 8.96% with 51 consecutive years of payments.

Analysis

ConAgra’s announced capacity push into protein shifts its risk profile from margin-stable packaged groceries toward a higher fixed-cost, throughput-driven business. That makes unit economics (yield per line, utilization) and capex pacing the dominant drivers of EBITDA over the next 12–24 months, rather than short-term topline swings; a 60–80% utilization step-up on new lines would materially improve per-unit gross margin even if input costs remain elevated.

The more important second-order effect is on the upstream feed and co-packer ecosystem: increased in-house chicken volume compresses outsourcing demand and could depress spot contract volumes for regional processors while raising feed procurement scale — benefiting large, integrated feed suppliers and pressuring smaller contract producers. Also expect trade dynamics: retailers will test promotional intensity as grocers balance staple volume retention against margin, which could force temporary category-level margin erosion across peers.

Key catalysts and risk windows are immediate (earnings and guidance revisions over the next 30–90 days), medium term (12–18 months as capacity comes online and procurement contracts roll), and longer term (2–3 years if portfolio mix permanently shifts toward protein). Tail risks include a sharp commodity spike (feed/energy) that erases any per-unit gains, or secular demand downshift for branded private-label swap that reduces pricing power; conversely, disciplined execution on capex and working capital could deliver a 20–40% normalization uplift to multiples within 12–18 months.

Key Decisions for Investors

• Pair trade (6–12 months): Long CAG (1–2% NAV) / Short CPB (equal notional). Rationale: asymmetric upside if ConAgra’s Fayetteville ramp improves unit margins while Campbell shows weaker operational leverage. Target gross return 25–35%, stop-loss 12% on either leg; rebalance monthly against utilization updates.
• Options play (18–24 months): Buy CAG LEAPS calls (≈Jan 2028) sized at 0.5–1.0% NAV and fund by selling nearer-term call spreads 2–3 months out to reduce premium. Exit triggers: failed utilization progress at next two quarter updates or guidance cut; upside case captures 3x+ payoff if margin recovery materializes.
• Short standalone weakness in a peer (3–6 months): Short CPB (or GIS) if promotional intensity increases post-earnings; size 0.5–1% NAV as a hedge to staples exposure. Target 15–20% downside, stop 8% loss; rationale is lower operating leverage and heavier exposure to categories where grocers will pull back on pricing.
• Event-strategy (earnings): Small long ahead of the next quarter (0.5% NAV) paired with a protective put (30–45 days) to buy optionality into a potential guidance re-affirmation or better-than-feared organic sales. If earnings are neutral-to-positive and guidance holds, sell covered calls to harvest implied volatility and convert to yield; close on clear utilization guidance changes.